Geneva Health partners with Ochsner in remote cardiac monitoring

EKG rhythm
Recently, Geneva reported triple-digit revenue growth in 2018, alongside a tripling of its client base and its workforce. (Pixabay / PublicDomainPictures)

Ochsner Health System has tapped Geneva Health Solutions to manage data collection and remote monitoring of its patients with implanted cardiac devices across the southern U.S.

Geneva will gather data from implanted pacemakers, defibrillators, loop recorders and other devices and integrate them into the health system’s established Epic electronic medical record. It will be the first time Geneva’s cloud-based platform will be used in the region, spanning Ochsner’s 30 hospitals and more than 80 health centers across Louisiana, Arkansas, Mississippi, Alabama and Georgia.

It will also allow providers to schedule device follow-ups or respond to issues—as well as manage alerts for events such as atrial fibrillation or other indicators of heart failure—as it aggregates data from home use, in addition to office, ER or hospital visits.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Recently, Geneva reported triple-digit revenue growth in 2018, alongside a tripling of its client base and its workforce, and said it expects an explosion of cardiac device data over the next year.

Describing a “data deluge” from implanted devices, Geneva CEO Yuri Sudhakar pointed to how cardiac practice staff can be overextended and overwhelmed in trying to deal with the amount of incoming information.

Currently, Geneva’s remote monitoring includes more than 30,000 patients at over 45 cardiology sites, the company said.

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.